Details of the Drug Combinations

General Information of This Drug (ID: DM6KU93)

Drug Name
Alvespimycin hydrochloride   DM6KU93
Synonyms
Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Refractory hematologic malignancy 2A85.5 Phase 1 [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

41 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Alvespimycin hydrochloride + Ruxolitinib DCP742A Ruxolitinib T-cell leukemia/lymphoma (Cell Line: ED-40515) [2]
Alvespimycin hydrochloride + Carfilzomib DCM7P27 Carfilzomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Artemether DCKKQ3Y Artemether DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + PMID28460551-Compound-2 DCYFT79 PMID28460551-Compound-2 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Panobinostat DC7EWT4 Panobinostat DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Panobinostat DCWVZ54 Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Ixazomib DCRPASH Ixazomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Marizomib DCL0F5H Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Methylene blue DCBDZN4 Methylene blue DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Omacetaxine mepesuccinate DCJED06 Omacetaxine mepesuccinate DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Naltrexone DCJ0J9T Naltrexone DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Quinine DCAS3SW Quinine DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Piperaquine DCBOLZK Piperaquine DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Vorinostat DCDKQZC Vorinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Alvespimycin hydrochloride + Atovaquone DC3GEXQ Atovaquone DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + Sapanisertib DC2UGCJ Sapanisertib DD2 (Cell Line: DD2) [2]
Alvespimycin hydrochloride + GSK2126458 DC9LAY6 GSK2126458 Hepatoblastoma (Cell Line: HB3) [3]
Alvespimycin hydrochloride + Chloroquine DC0HP0U Chloroquine Hepatoblastoma (Cell Line: HB3) [3]
Alvespimycin hydrochloride + Piperaquine DCE0C2J Piperaquine Hepatoblastoma (Cell Line: HB3) [3]
Alvespimycin hydrochloride + ZSTK474 DCBS7DU ZSTK474 Hepatoblastoma (Cell Line: HB3) [3]
Alvespimycin hydrochloride + Sapanisertib DCQOW40 Sapanisertib Hepatoblastoma (Cell Line: HB3) [3]
Artemisinin + Alvespimycin hydrochloride DC6B3P0 Artemisinin DD2 (Cell Line: DD2) [2]
AZD8330 + Alvespimycin hydrochloride DC7DTHY AZD8330 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
BGT226 + Alvespimycin hydrochloride DCCXF0J BGT226 DD2 (Cell Line: DD2) [2]
BMS-754807 + Alvespimycin hydrochloride DCQM0GG BMS-754807 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Buparlisib + Alvespimycin hydrochloride DCO1U3K Buparlisib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Crizotinib + Alvespimycin hydrochloride DCO945F Crizotinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Erlotinib + Alvespimycin hydrochloride DC6MF6L Erlotinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
KN-62 + Alvespimycin hydrochloride DCL70L8 KN-62 DD2 (Cell Line: DD2) [2]
Lumefantrine + Alvespimycin hydrochloride DC7M0ER Lumefantrine DD2 (Cell Line: DD2) [2]
Mebendazole + Alvespimycin hydrochloride DCJ8RBP Mebendazole Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Mefloquine + Alvespimycin hydrochloride DCD4RTL Mefloquine DD2 (Cell Line: DD2) [2]
NVP-AUY922 + Alvespimycin hydrochloride DC34JFJ NVP-AUY922 DD2 (Cell Line: DD2) [2]
NVP-AUY922 + Alvespimycin hydrochloride DC5LVBA NVP-AUY922 Hepatoblastoma (Cell Line: HB3) [3]
Omacetaxine mepesuccinate + Alvespimycin hydrochloride DCD6GKF Omacetaxine mepesuccinate Hepatoblastoma (Cell Line: HB3) [3]
ONC201 + Alvespimycin hydrochloride DCIQUG5 ONC201 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
PD-0325901 + Alvespimycin hydrochloride DCIY37S PD-0325901 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Pyrazinamide + Alvespimycin hydrochloride DCANT7X Pyrazinamide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Ridaforolimus + Alvespimycin hydrochloride DC7LKWQ Ridaforolimus Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
SCH 727965 + Alvespimycin hydrochloride DCLAQA8 SCH 727965 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
Selumetinib + Alvespimycin hydrochloride DCEDQ0L Selumetinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 41 DrugCom(s)

References

1 ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.